Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Practical Bayesian guidelines for phase IIB clinical trials

P F Thall1, R Simon

  • 1Department of Biomathematics, Anderson Cancer Center, University of Texas, Houston 77030.

Biometrics
|June 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Bone marrow transplantation·2016
Same author

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Leukemia·2016
Same author

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.

Leukemia·2015
Same author

A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience.

Bone marrow transplantation·2013
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
Same journal

A Bayesian phase I/II platform design with data augmentation accounting for delayed outcomes.

Biometrics·2026
See all related articles

This study introduces Bayesian guidelines for Phase IIB clinical trials, enabling continuous data monitoring to determine if a new treatment E shows promise compared to standard therapy S. The approach ensures efficient decision-making within set sample size limits.

Area of Science:

  • Clinical Trial Design
  • Biostatistics
  • Pharmacoeconomics

Background:

  • Phase IIB clinical trials are crucial for evaluating new treatments (E) against standard therapies (S) before large-scale randomized trials.
  • Current Phase IIB trial designs often overlook explicit quantification of uncertainty in standard therapy response rates (θs).
  • Continuous data monitoring is essential for adaptive trial designs but requires robust statistical frameworks.

Purpose of the Study:

  • To propose practical Bayesian guidelines for Phase IIB clinical trials with binary outcomes and continuous data monitoring.
  • To provide a framework for deciding if a new treatment (E) is promising relative to a standard therapy (S), incorporating uncertainty in S's response rate.
  • To establish decision boundaries and sample size distributions for adaptive Phase IIB trial designs.

Related Experiment Videos

Main Methods:

  • Development of Bayesian decision-making guidelines for comparative effectiveness in Phase IIB trials.
  • Incorporation of an informative prior for the standard therapy response rate (θs).
  • Continuous data monitoring until a decision (promising or not promising) is reached or maximum sample size is met.

Main Results:

  • The proposed Bayesian design provides clear decision boundaries for trial termination.
  • It yields a probability distribution for the sample size at termination, aiding in resource planning.
  • Operating characteristics are defined under fixed response probabilities, allowing for performance evaluation.

Conclusions:

  • The Bayesian guidelines offer a practical and statistically sound approach for Phase IIB trial design and interpretation.
  • This method explicitly addresses uncertainty in standard therapy response rates, leading to more robust treatment evaluations.
  • The adaptive design facilitates efficient decision-making, optimizing resource allocation in early-phase drug development.